We read with interest the recent work by Carbonnel et al1 reporting the results from the METEOR (Controlled, Randomized, Double-Blind, Multicentre Study Comparing Methotrexate vs Placebo in Steroid Dependant Ulcerative Colitis) trial. We agree with the authors about the relevance of this study, because this is the first trial that evaluated an adequate dosage of methotrexate administered parenterally in ulcerative colitis (UC). Although several retrospective and prospective open-label studies suggested that 25 mg of parenteral methotrexate might be an effective therapy in UC,2 the only randomized, placebo-controlled trial of methotrexate in UC tested oral methotrexate at a suboptimal dosage of 12.5 mg weekly, giving negative results.